## Appendix Table

Characteristics of Patients with Type 2 Diabetes Mellitus

|  | All | SGLT2i as preferred agent[2] | GLP1-RA as preferred agent[3] | Either agent recommended[4] | No comorbid conditions[5] |
| :---: | :---: | :---: | :---: | :---: | :---: |
| Demographic Characteristics |  |  |  |  |  |
| Number | 13,350 | 1,788 (13.4\%) | 226 (1.7\%) | 2,421 (18.1\%) | 8,415 (63.0\%) |
| Age, years | $65.2 \pm 13.2$ | $69.8 \pm 11.5$ | $74.3 \pm 11.6$ | $71.1 \pm 11.3$ | $61.6 \pm 12.8$ |
| Female | 6,274 (47.0\%) | 721 (40.3\%) | 118 (52.2\%) | 1,241 (51.3\%) | 4,000 (47.5\%) |
| Self-identified Race |  |  |  |  |  |
| Black | 1,652 (12.4\%) | 152 (8.5\%) | 22 (9.7\%) | 221 (9.1\%) | 1229 (14.6\%) |
| Hispanic | 1,326 (9.9\%) | 70 (3.9\%) | 17 (7.5\%) | 143 (5.9\%) | 1078 (12.8\%) |
| Other | 372 (2.8\%) | 20 (1.1\%) | 6 (2.7\%) | 33 (1.4\%) | 306 (3.6\%) |
| White | 8,857 (66.3\%) | 1473 (82.4\%) | 168 (74.3\%) | 1910 (78.9\%) | 4873 (57.9\%) |
| Asian | 1,075 (8.1\%) | 67 (3.7\%) | 13 (5.8\%) | 101 (4.2\%) | 880 (10.5\%) |
| Unknown | 68 (0.5\%) | 6 (0.3\%) | 0 (0\%) | 13 (0.5\%) | 49 (0.6\%) |
| Comorbid Conditions and Health Status |  |  |  |  |  |
| Charlson comorbidity score | $4.8 \pm 2.9$ | $5.8 \pm 3.0$ | $8.2 \pm 2.8$ | $5.7 \pm 3.0$ | $4.1 \pm 2.5$ |
| Hypertension | 10,579 (79.2\%) | 1,679 (93.9\%) | 193 (85.4\%) | 2,181 (90.1\%) | 6,060 (72.0\%) |
| Heart Failure | 1,639 (12.3\%) | 1,239 (69.3\%) | 29 (12.8\%) | 0 (0\%) | 0 (0\%) |
| Chronic Kidney Disease | 3,067 (23.0\%) | 895 (50.1\%) | 225 (99.6\%) | 1,455 (60.1\%) | 0 (0\%) |
| Atherosclerotic Cardiovascular Disease | 2,955 (22.1\%) | 1,300 (72.7\%) | 59 (26.1\%) | 1,201 (49.6\%) | 0 (0\%) |
| Coronary Artery Disease | 2,949 (22.1\%) | 1,294 (72.4\%) | 59 (26.1\%) | 1,201 (49.6\%) | 0 (0\%) |
| Cerebrovascular Disease | 1,121 (8.4\%) | 722 (40.4\%) | 15 (6.6\%) | 12 (0.5\%) | 0 (0\%) |
| Peripheral Vascular Disease | 1,231 (9.2\%) | 821 (45.9\%) | 19 (8.4\%) | 17 (0.7\%) | 0 (0\%) |
| Pancreatitis | 694 (5.2\%) | 321 (18.0\%) | 0 (0\%) | 3 (0.1\%) | 0 (0\%) |
| Treated with Statin | 8,964 (67.1\%) | 1,173 (65.6\%) | 182 (80.5\%) | 1,834 (75.8\%) | 5,678 (67.5\%) |
| Treatment with Ace inhibitor or ARB | 8,754 (65.6\%) | 1,285 (71.9\%) | 143 (63.3\%) | 1,786 (73.8\%) | 5,284 (62.8\%) |
| Recent Blood Pressure (mmHg) | 130.6/73.9 | 132.1/72.8 | 134.6/69.6 | 131.6/72.8 | 129.8/74.9 |
| Body Mass Index (kg/m ${ }^{2}$ ) | $31.9 \pm 6.7$ | 32.1 $\pm 6.9$ | $32.6 \pm 7.0$ | $32.4 \pm 6.6$ | $31.8 \pm 6.7$ |
| <25 | 1,677 (12.6\%) | 240 (13.4\%) | 28 (12.4\%) | 270 (11.2\%) | 1,066 (12.7\%) |
| 25-30 | 3,901 (29.2\%) | 503 (28.1\%) | 62 (27.4\%) | 682 (28.2\%) | 2,496 (29.7\%) |
| 30-35 | 3,801 (28.5\%) | 533 (29.8\%) | 60 (26.5\%) | 703 (29.0\%) | 2,360 (28.0\%) |
| 35-40 | 2,115 (15.8\%) | 307 (17.2\%) | 38 (16.8\%) | 437 (18.1\%) | 1,257 (14.9\%) |
| $>40$ | 1,443 (10.8\%) | 192 (10.7\%) | 32 (14.2\%) | 306 (12.6\%) | 872 (10.4\%) |
| Missing | 413 (3.1\%) | 13 (0.7\%) | 6 (2.7\%) | 23 (1.0\%) | 364 (4.3\%) |
| Recent LDL (mg/dL) | $84.9 \pm 33.2$ | $80.8 \pm 32.6$ | $75.6 \pm 32.7$ | $80.9 \pm 31.3$ | $87.8 \pm 33.7$ |
| eGFR (m/min/ $1.73 \mathrm{~m}^{2}$ ) [1] |  |  |  |  |  |
| >60 | 10,075 (75.5\%) | 1,151 (64.4\%) | 0 (0.0\%) | 985 (40.7\%) | 7,939 (94.3\%) |
| 45-60 | 1,620 (12.1\%) | 377 (21.1\%) | 0 (0.0\%) | 917 (37.9\%) | 326 (3.9\%) |
| 30-44 | 808 (6.1\%) | 252 (14.1\%) | 0 (0.0\%) | 512 (21.1\%) | 44 (0.5\%) |
| 15-29 | 249 (1.9\%) | 0 (0.0\%) | 226 (100.0\%) | 1 (0.0\%) | 12 (0.1\%) |
| <15 | 136 (1.0\%) | 0 (0.0\%) | 0 (0.0\%) | 0 (0.0\%) | 0 (0.0\%) |
| Kidney Failure | 353 (2.6\%) | 0 (0.0\%) | 0 (0.0\%) | 0 (0.0\%) | 0 (0.0\%) |
| Urine Albumin-to-Creatinine Ratio |  |  |  |  |  |
| $<30 \mathrm{mg} / \mathrm{dL}$ | 7,591 (56.9\%) | 630 (35.2\%) | 23 (10.2\%) | 1,252 (51.7\%) | 5,516 (65.5\%) |
| 30-300 mg/dL | 2,453 (18.4\%) | 257 (14.4\%) | 70 (31.0\%) | 720 (29.7\%) | 1,316 (15.6\%) |
| $>300 \mathrm{mg} / \mathrm{dL}$ | 788 (5.9\%) | 614 (34.3\%) | 94 (41.6\%) | 0 (0.0\%) | 0 (0.0\%) |
| Missing | 2,518 (18.9\%) | 287 (16.1\%) | 39 (17.3\%) | 449 (18.5\%) | 1,583 (18.8\%) |
| Hemoglobin A1c |  |  |  |  |  |
| <7\% (<8.6 mmol/ ) | 6,916 (51.8\%) | 894 (50.0\%) | 115 (50.9\%) | 1,301 (53.7\%) | 4,299 (51.1\%) |
| 7-8\% (8.6-10.1 mmo/L) | 3,114 (23.3\%) | 407 (22.8\%) | 51 (22.6\%) | 587 (24.2\%) | 1,957 (23.3\%) |
| 8-9\% (10.1-11.7 mmol/ ) | 1,544 (11.6\%) | 215 (12.0\%) | 37 (16.4\%) | 273 (11.3\%) | 971 (11.5\%) |
| $>9 \%$ ( $>11.7 \mathrm{mmol} / \mathrm{L}$ ) | 1,658 (12.4\%) | 258 (14.4\%) | 23 (10.2\%) | 249 (10.3\%) | 1,099 (13.1\%) |
| Missing | 118 (0.9\%) | 14 (0.8\%) | 0 (0.0\%) | 11 (0.5\%) | 89 (1.1\%) |

Numeric variables shown as mean $\pm$ standard deviation. Categorical variables displayed as count (percent of total).
[1] eGFR is estimated GFR calculated by the abbreviated MDRD equation:
$186 \times$ (Creatinine/88.4)-1.154 x (Age)-0.203 x (0.742 if female) x ( 1.210 if Black)
[2] Patients with diagnosis of HF, eGFR $>30 \mathrm{ml} / \mathrm{min} / 1.73 \mathrm{~m}^{2}$ or diagnosis of CKD with urinary albumin to creatinine ratio (UACR) $>300 \mathrm{mg} / \mathrm{g}$.
[3] Patients with a history of HF or CKD with eGFR less than 30 and greater than 14 $\mathrm{ml} / \mathrm{min} / 1.73 \mathrm{~m}^{2}$ and without history of pancreatitis.
[4] Patients without diagnosis of HF, with diagnosis of CKD and with UACR $30-300 \mathrm{mg} / \mathrm{g}$, or diagnosis of ASCVD.
[5] Patients without diagnosis of HF, CKD, or ASCVD.

